Literature DB >> 28888967

Twenty-five-gauge sutureless lensectomy in infants with congenital cataract.

Marcia Beatriz Tartarella1, João Borges Fortes Filho2.   

Abstract

PURPOSE: To evaluate the incidence of intra- and postoperative complications of transconjunctival 25-gauge (25G) sutureless pars plicata lensectomy.
METHODS: The medical records of patients <12 months of age with congenital cataracts who underwent 25G sutureless lensectomy were reviewed retrospectively. Patients were evaluated at postoperative days 1, 7, 15, 30, 60, and 90 and every 3 months thereafter. Visual acuity outcomes and intra- and postoperative complications were described and analyzed.
RESULTS: A total of 72 eyes of 44 infants were included; 28 patients (64%) had bilateral cataract. Median follow-up was 28 months (range, 12-93 months). In 47 eyes (81%) there was improved visual acuity after surgery. Intraoperative adverse events occurred in 9 eyes (13%). Postoperative complications occurred in 14 eyes (19%): 6 eyes (8%) had secondary visual axis opacification, 6 eyes (8%) had secondary glaucoma, 1 eye (1%) had posterior synechiae, and 1 eye (1.4%) had retinal detachment.
CONCLUSIONS: Transconjunctival pars plicata 25G sutureless lensectomy is a minimally invasive technique for congenital cataract treatment. No postoperative complications were observed in 81% of eyes. Visual acuity improved in 81% of the operated eyes.
Copyright © 2017 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28888967     DOI: 10.1016/j.jaapos.2017.07.203

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  1 in total

1.  Comparison of different surgical approaches for pediatric cataracts: complications and rates of additional surgery during long-term follow-up.

Authors:  Camila R Koch; Newton Kara-Junior; Marcony R Santhiago; Marta Morales
Journal:  Clinics (Sao Paulo)       Date:  2019-07-29       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.